MedImmune doubles HQ for growing workforce; UK set to switch Flomax to OTC;

> To handle the hundreds of new hires tallied from 2008 and envisioned for 2009, MedImmune plans to nearly double its 361,000-square-foot Maryland headquarters in the next three years. Report

> The UK looks set to be the first country in the world to switch Boehringer Ingelheim's Flomax to non-prescription status for treating benign prostatic hyperplasia (BPH). Report

> Germany's Merck KGaA won EU approval to extend the use of Erbitux (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Report

> Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012, according to a new report from Decision Resources. Release

> Generics maker Actavis said it has received FDA approval to market its version of Wellbutrin XL 150mg tablets, and that it has started distributing the product. Release

> Impax, another generics firm, got final FDA approval for its own version of Wellbutrin XL 150mg tablets and has launched the product. Report

> Sanofi-Aventis signed a three-year contract to extend the use of Advanced Chemistry Development's software throughout its R&D sites worldwide. Report

> Although they've fallen from the record highs posted in August, biotech stocks aren't as risky as many fear--or expensive, says a report by Barron's. Report

> Shares of Switzerland's Basilea Pharmaceutica were hammered after the developer announced that it faced a major delay in gaining an approval from the FDA for its antibiotic ceftobiprole. Report

> The UK's Stem Cell Sciences, which has been commercializing stem cell technology, asked for a temporary suspension in the trading of its shares as it reviews a lineup of strategic options that include a possible sale of assets, refinancing and a merger. Report

> Poniard Pharmaceuticals says it will take a look at "strategic alternatives" for the developer's preclinical development program, a decision that triggered the departure of Dr. David Karlin, the head of clinical development. Report

> Shares of Belgium's Galapagos surged on the news that it had partnered with Germany's MorphoSys AG to develop antibodies for bone and joint diseases. Report

And Finally... A drop in blood potassium levels caused by diuretics prescribed for high blood pressure could be the reason why people on those drugs are at risk for developing type 2 diabetes. Release 

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.